Recombinant NKG2A (Monalizumab Biosimilar) 抗体
Research Grade
适用: 人
ELISA, WB
宿主: Humanized
Monoclonal
unconjugated
Recombinant Antibody
-
- 抗原 See all NKG2A (Monalizumab Biosimilar) products
- NKG2A (Monalizumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
-
Humanized
- Expression System
- Mammalian cells
-
克隆类型
- 单克隆
-
标记
- This NKG2A (Monalizumab Biosimilar) antibody is un-conjugated
- 应用范围
- ELISA, Western Blotting (WB)
- 原理
- Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade
- 产品特性
- Antibody Type: IgG4-kappa
- 纯化方法
- Recombinant antibody expressed in mammalien cells and purified.
- 纯度
- > 85%
- 质量等级
- Research Grade
- 亚型
- IgG4
-
-
- 限制
- 仅限研究用
-
- 缓冲液
- PBS buffer PH7.5
- 储存条件
- -80 °C
- 储存方法
- store at -80°C
-
- 抗原
- NKG2A (Monalizumab Biosimilar)
- Abstract
- NKG2A (Monalizumab Biosimilar) 产品
- 背景
- Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
- CAS-编号
- 1228763-95-8
-
You are here:
